Nasdaq · Health Care · Drug Manufacturers - General
GILD
Gilead Sciences, Inc.
Develops antiviral drugs for HIV and hepatitis, alongside a growing portfolio of cancer cell therapies.
$138.36+0.16%
Close · 2026-08-14$110$120$130$140$150
NovFebMayAug
$106.44
$155.3852-week range, last close at 65% of the range
- 1W
- +3.87%
- 1M
- +5.06%
- 3M
- +7.48%
- 6M
- -9.63%
- YTD
- +14.11%
- 1Y
- +19.28%
- Avg vol 20d
- 6.7M
- RVOL
- 0.49
- HOLD band
Fundamentalsas of 2026-08-14
- Mkt cap
- $171.56B
- P/E
- —
- Fwd P/E
- 14.0
- EPS
- $-2.65
- Div yield
- 2.37%
- Beta
- 0.34
- Employees
- 17K
- Next earnings
- 2026-10-29
Rating & verdict historyoldest → newest
100.0% correct-0.11% avg moveBUY 0/0 · HOLD 1/1 · SELL 0/0
| Date | Call | Outcome | Return | Takeaway |
|---|---|---|---|---|
| 2026-08-14 | Subscribers | — | — | Subscribe to read |
| 2026-08-13 | Subscribers | — | — | Subscribe to read |
| 2026-08-12 | Subscribers | — | — | Subscribe to read |
| 2026-08-11 | Subscribers | — | — | Subscribe to read |
| 2026-08-10 | Subscribers |